Cathepsin activatable Cy5 fluorescent imaging probe LUM015

Drug Overview

Cathepsin activatable Cy5 fluorescent imaging probe LUM015 is a groundbreaking medical innovation. Rather than being a traditional treatment pill or chemotherapy, it is an advanced Targeted Therapy and “Smart Drug” used exclusively as an imaging agent during cancer surgery. It acts like a high-tech, glowing highlighter that helps surgeons see microscopic cancer cells that might otherwise be left behind in the body.

• Generic Name: Pegulicianine (formerly known in research as LUM015)
• US Brand Names: LUMISIGHT™
• Drug Class: Optical Imaging Agent (Fluorescent Probe)
• Route of Administration: Intravenous (IV) injection
• FDA Approval Status: FDA-approved (as of April 2024) for use alongside a specific imaging device (the Lumicell Direct Visualization System) during breast cancer surgeries.

What Is It and How Does It Work? (Mechanism of Action)

Pegulicianine is a “Smart Drug” designed to find cancer and light it up. When a surgeon removes a tumor, it is very hard to tell with the naked eye if all the cancer cells are completely gone.

At the molecular level, pegulicianine is an inactive molecule (a “prodrug”) when it first enters your blood. It is made of three main parts: a fluorescent dye (the part that glows), a “quencher” (a cover that keeps the dye dark), and a peptide backbone holding them together.

Here is how it targets cancer:

1. Seeking the Enzymes: Cancer cells, and the tissue immediately surrounding them, produce unusually high amounts of specific enzymes called cathepsins and matrix metalloproteases.
2. Breaking the Lock: When the pegulicianine molecule reaches the tumor area, these enzymes act like chemical scissors. They cut the peptide backbone of the drug.
3. The Glowing Signal: Once the backbone is cut, the “quencher” falls off. The fluorescent dye is instantly activated.

During surgery, the doctor uses a special handheld camera that shines a specific light into the surgical cavity. Because the drug was activated only by the cancer’s enzymes, any remaining cancer cells will glow on the doctor’s screen, telling them exactly where to remove more tissue.

FDA Approved Clinical Indications

This imaging agent is currently approved for a very specific surgical purpose.

Oncological uses:

• Breast Cancer Surgery: Used in adults as an add-on tool during a lumpectomy (breast-conserving surgery). It helps detect cancerous tissue remaining inside the breast cavity after the main tumor has been removed.

Non-oncological uses:

• There are currently no FDA-approved uses outside of cancer surgery.

Dosage and Administration Protocols

Because pegulicianine is a surgical imaging tool, it is given only once, on the day of your surgery, by a healthcare professional in a hospital or clinic.

Dose Adjustments:

• Renal and Hepatic Insufficiency: Because this is a one-time preoperative imaging dose, there are no standard dose reductions specifically required for mild to moderate kidney or liver issues. However, your surgical team will review your complete metabolic health before clearing you for surgery.

Clinical Efficacy and Research Results

Recent clinical trial data (2020–2025) has shown that pegulicianine significantly improves the precision of breast cancer surgeries.

• The INSITE Phase 3 Trial (2024 Data): In a major study involving nearly 400 breast cancer patients, pegulicianine proved to have an overall diagnostic accuracy of 84%.
• Preventing Second Surgeries: During this trial, surgeons first removed the main tumor using standard techniques. Then, they used pegulicianine and its camera system to check the empty cavity. In about 7.6% of patients (27 out of 357), the glowing drug revealed leftover cancer that the surgeons successfully removed.
• Accuracy Metrics: The drug showed a high “specificity” of 85.2%, meaning it is very good at correctly identifying healthy tissue so that surgeons do not remove more breast tissue than necessary.

Safety Profile and Side Effects

Pegulicianine is generally safe and exits the body quickly, but because it contains certain chemical compounds, it can trigger allergic reactions.

Black Box Warning

• Anaphylaxis and Serious Hypersensitivity Reactions: Pegulicianine carries the FDA’s strictest warning for severe allergic reactions. Because the drug contains Polyethylene Glycol (PEG), patients with PEG allergies can experience life-threatening swelling, breathing trouble, or blood pressure drops immediately after the IV injection.

Common Side Effects (>10%)

• Chromaturia (Abnormal Urine Color): The most common side effect by far (affecting up to 85% of patients). Your urine may turn a noticeable blue or green color for a few days after surgery as your kidneys flush the dye out of your body.
• Mild Allergic Reactions: Mild rashes or itching near the IV site.

Serious Adverse Events

• Anaphylaxis: A severe, whole-body allergic reaction requiring emergency medical treatment.
• Risk of Misdiagnosis: While rare, the drug can sometimes cause a “false positive” (glowing where there is no cancer) or a “false negative” (failing to glow where cancer is present), which is why it is used only as an add-on to standard surgical care, not a replacement.

Management Strategies:

• For Allergies: The medical team will have emergency resuscitation equipment and medicines (like epinephrine) ready in the room before the IV is started. You will be closely monitored for at least 30 minutes after the injection.
• For Urine Color Changes: No medical treatment is needed; drinking plenty of water will help clear the dye naturally.

Research Areas

While pegulicianine is currently approved for breast cancer, researchers are actively studying its ability to highlight other types of tumors. Current research (2024-2026) is investigating whether this cathepsin-activated probe can be used during surgeries for gastrointestinal (colon) cancers, lung cancers, and soft tissue sarcomas. Scientists are also studying how the drug interacts with macrophages special immune cells in the tumor microenvironment to better understand how tumors hide from the body’s natural defenses.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Allergy Screening: You must tell your doctor if you have ever had an allergic reaction to Polyethylene Glycol (PEG), which is found in many laxatives (like Miralax) and some vaccines.
• Surgical Clearance: Standard pre-surgery bloodwork (Complete Blood Count and metabolic panels).

Precautions During Treatment

• Dye Interactions: If you are having a “sentinel lymph node biopsy” on the same day, your surgeon must be careful about which blue dyes they use, as certain dyes (like methylene blue) can interfere with pegulicianine’s fluorescent signal.
• Post-Injection Monitoring: You must remain under the observation of nurses for a short period immediately after the drug is injected into your vein, before you are taken into the operating room.

“Do’s and Don’ts” List

• DO tell your surgical team about all allergies you have, no matter how small they seem.
• DO drink plenty of fluids in the days following your surgery to help your kidneys flush the harmless dye from your system.
• DO expect your urine to look unusually blue or green for 1 to 3 days after the procedure. This is completely normal and safe.
• DON’T panic if the surgeon tells you they found more tissue using the Lumicell system; the drug did its job by finding hidden cells during the first surgery, which lowers the chances of needing a second surgery later.

Legal Disclaimer

This guide is intended for educational and informational purposes only and does not constitute medical advice. Pegulicianine (LUMISIGHT™) is a specialized surgical imaging agent that must only be administered by qualified healthcare professionals in a controlled clinical setting. Always consult with your oncologist and surgical team regarding your specific diagnosis, surgical plan, and any risks associated with anesthesia and surgical medications. Never disregard professional medical advice or delay seeking it based on the information provided in this guide.